Douglas M. Lankler net worth and biography

Douglas Lankler Biography and Net Worth

EVP of Pfizer
Doug Lankler joined Pfizer in 1999 and currently serves as general counsel. Prior to being named general counsel, Doug was Pfizer's chief compliance and risk officer, a role he assumed in 2006.

Prior to joining the company, Doug was with the United States Department of Justice as an Assistant U.S. Attorney in the Southern District of New York. Doug was a recipient of the United States Attorney General's Distinguished Service Award.

Doug graduated from the State University of New York at Albany and Cornell Law School. He and his wife, Jill, have three children and reside in Larchmont, N.Y.

What is Douglas M. Lankler's net worth?

The estimated net worth of Douglas M. Lankler is at least $6.87 million as of April 29th, 2020. Mr. Lankler owns 135,375 shares of Pfizer stock worth more than $6,867,574 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Lankler may own. Additionally, Mr. Lankler receives a salary of $3,780,000.00 as EVP at Pfizer. Learn More about Douglas M. Lankler's net worth.

How old is Douglas M. Lankler?

Mr. Lankler is currently 56 years old. There are 7 older executives and no younger executives at Pfizer. The oldest executive at Pfizer is Mr. Frank A. D'Amelio, CFO & Exec. VP, who is 64 years old. Learn More on Douglas M. Lankler's age.

What is Douglas M. Lankler's salary?

As the EVP of Pfizer Inc., Mr. Lankler earns $3,780,000.00 per year. There are 5 executives that earn more than Mr. Lankler. The highest earning executive at Pfizer is Dr. Albert Bourla D.V.M., DVM, Ph.D., Chairman & CEO, who commands a salary of $11,070,000.00 per year. Learn More on Douglas M. Lankler's salary.

How do I contact Douglas M. Lankler?

The corporate mailing address for Mr. Lankler and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Douglas M. Lankler's contact information.

Has Douglas M. Lankler been buying or selling shares of Pfizer?

Douglas M. Lankler has not been actively trading shares of Pfizer in the last ninety days. Most recently, Douglas M. Lankler sold 40,000 shares of the business's stock in a transaction on Friday, November 26th. The shares were sold at an average price of $54.37, for a transaction totalling $2,174,800.00. Learn More on Douglas M. Lankler's trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 41,126 shares worth more than $2,075,003.28. The most recent insider tranaction occured on June, 7th when SVP Jennifer B Damico sold 4,218 shares worth more than $227,603.28. Insiders at Pfizer own 0.1 % of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 6/7/2022.

Douglas M. Lankler Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/26/2021Sell40,000$54.37$2,174,800.00View SEC Filing Icon  
4/29/2020Sell65,000$37.85$2,460,250.00135,375View SEC Filing Icon  
2/1/2019Sell5,000$42.75$213,750.0083,592View SEC Filing Icon  
1/30/2019Sell38,800$41.19$1,598,172.0083,592View SEC Filing Icon  
3/13/2018Sell50,000$36.89$1,844,500.00133,057View SEC Filing Icon  
5/4/2016Sell29,700$33.69$1,000,593.00124,920View SEC Filing Icon  
See Full Table

Douglas M. Lankler Buying and Selling Activity at Pfizer

This chart shows Douglas M Lankler's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $50.73
Low: $50.35
High: $51.03

50 Day Range

MA: $46.17
Low: $41.75
High: $51.08

2 Week Range

Now: $50.73
Low: $41.44
High: $61.71


16,908,214 shs

Average Volume

24,548,986 shs

Market Capitalization

$284.76 billion

P/E Ratio


Dividend Yield